MT3 and central nervous system cancer: Importantly, Mehrian-Shai et al. 17 recently reported that, in glioblastoma patients, high expression of including MT3 was associated with poor patient survival whereas low MT levels corresponded to good prognosis, suggesting the prognostic implications of Mts in glioma.